B Cell Malignancies (including B Cell Lymphoma, Multiple Myeloma and B-CLL)

Dear Colleagues,

B cell malignancies comprise a heterogeneous group of cancers, including B cell lymphomas, B cell leukemias and plasma cell dyscrasias, and combined constitute the fifth most common cancer in adults. The majority of B cell malignancies originate from germinal center B cells where the enzyme activation-induced deaminase (AID), essential for creating antibody  diversification, can  introduce  mutations of proto-oncogenes and chromosomal translocations that result in cancer development.

Over the last decades, basic research on the pathogenesis of B cell malignancies has provided significant insights about the mechanisms that underlie disease progression, malignant cell survival and drug resistance, often leading to successful shifts in treatment paradigms. However, despite these advances, many B cell malignancies are still considered incurable.

This Special Issue will highlight the development of novel treatment options, including targeted therapies, combination treatment and immunotherapeutic approaches that cover basic, translational and (pre)clinical aspects aiming to improve treatment of B cell malignancies.

Dr. Victor Peperzak
Dr. Marta Cuenca Lopera
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.